SEEL Seelos Therapeutics Quick Ratio

This chart of the market valuation for Seelos Therapeutics (SEEL) on the GURU.Markets platform is fixed at 0.00. Price growth is possible contingent upon successful intranasal ketamine trials and new partnerships. The business relies on developing innovative therapies for rare nervous system pathologies; however, the lack of profitable products and a severe cash shortage create significant risks for the biotech's operational activities.

Quick liquidity determines the ability of a company to instantaneously settle short-term obligations without liquidating inventory. The dynamics of strict liquidity reflect the volume of available capital, excluding low-liquidity assets from the calculation. This metric aggregates cash and accounts receivable, revealing the investor's real financial reserve. For Seelos Therapeutics (SEEL), this is critical, as it guarantees uninterrupted funding for the network of contract laboratories and the procurement of substances for neuropreparations.